Metformin Preconditioning and Postconditioning to Reduce Ischemia Reperfusion Injury in an IsolatedEx VivoRat and Porcine Kidney Normothermic Machine Perfusion Model by Huijink, Tobias M et al.
 
 
 University of Groningen
Metformin Preconditioning and Postconditioning to Reduce Ischemia Reperfusion Injury in an
IsolatedEx VivoRat and Porcine Kidney Normothermic Machine Perfusion Model
Huijink, Tobias M; Venema, Leonie H; Posma, Rene A; de Vries, Nynke J; Westerkamp,
Andrie C; Ottens, Petra J; Touw, Daan J; Nijsten, Maarten W; Leuvenink, Henri G D
Published in:
Clinical and translational science
DOI:
10.1111/cts.12846
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Huijink, T. M., Venema, L. H., Posma, R. A., de Vries, N. J., Westerkamp, A. C., Ottens, P. J., Touw, D. J.,
Nijsten, M. W., & Leuvenink, H. G. D. (2020). Metformin Preconditioning and Postconditioning to Reduce
Ischemia Reperfusion Injury in an IsolatedEx VivoRat and Porcine Kidney Normothermic Machine
Perfusion Model. Clinical and translational science. https://doi.org/10.1111/cts.12846
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Citation: Clin Transl Sci (2020) 0, 1–9; doi:10.1111/cts.12846
ARTICLE
Metformin Preconditioning and Postconditioning to 
Reduce Ischemia Reperfusion Injury in an Isolated Ex Vivo 
Rat and Porcine Kidney Normothermic Machine Perfusion 
Model
Tobias M. Huijink1 , Leonie H. Venema1,* , Rene A. Posma2 , Nynke J. de Vries1, Andrie C. Westerkamp1, Petra J. Ottens1, 
Daan J. Touw3 , Maarten W. Nijsten2  and Henri G.D. Leuvenink1
Metformin may act renoprotective prior to kidney transplantation by reducing ischemia-reperfusion injury (IRI). This study 
examined whether metformin preconditioning and postconditioning during ex vivo normothermic machine perfusion (NMP) 
of rat and porcine kidneys affect IRI. In the rat study, saline or 300 mg/kg metformin was administered orally twice on the 
day before nephrectomy. After 15 minutes of warm ischemia, kidneys were preserved with static cold storage for 24 hours. 
Thereafter, 90 minutes of NMP was performed with the addition of saline or metformin (30 or 300 mg/L). In the porcine study, 
after 30 minutes of warm ischemia, kidneys were preserved for 3 hours with oxygenated hypothermic machine perfusion. 
Subsequently, increasing doses of metformin were added during 4 hours of NMP. Metformin preconditioning of rat kidneys 
led to decreased injury perfusate biomarkers and reduced proteinuria. Postconditioning of rat kidneys resulted, dose-de-
pendently, in less tubular cell necrosis and vacuolation. Heat shock protein 70 expression was increased in metformin-
treated porcine kidneys. In all studies, creatinine clearance was not affected. In conclusion, both metformin preconditioning 
and postconditioning can be done safely and improved rat and porcine kidney quality. Because the effects are minor, it is 
unknown which strategy might result in improved organ quality after transplantation.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Ischemia-reperfusion injury (IRI) negatively affects 
outcomes of kidney transplantation, whereas metformin 
has been proposed to attenuate IRI beyond its glucose-
lowering actions. Machine perfusion provides a platform 
to add protective agents, like metformin, prior to or during 
reperfusion to decrease IRI. Previous data showed that 
metformin preconditioning was able to improve hepatobil-
iary function during normothermic machine perfusion and 
subsequent transplantation of rat livers.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  In this study, potential beneficial effects of precondi-
tioning and postconditioning with metformin on IRI were 
evaluated in different isolated ex vivo normothermic ma-
chine perfusion models using rat and porcine kidneys.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  We show that both metformin preconditioning and 
postconditioning reduced rat and porcine kidney injury, 
but that the improvements were minor. It remains unknown 
whether addition of metformin during machine perfusion 
results in improved organ quality after transplantation. 
Moreover, we show that the use of in vivo toxic concen-
trations of metformin during machine perfusion was not 
associated with cellular damage, indicating that it seems 
to be safe to use these concentrations during ex vivo per-
fusion of kidneys.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔  Being widely implemented, machine perfusion is an 
ideal platform for pharmacological interventions to dimin-
ish or prevent IRI, and to test therapeutics in isolated ex 
vivo organs. As the effects of metformin were minor, it 
remains unclear whether it should be used as a renopro-
tective agent prior to transplantation. Our results do not 
necessarily advocate the use of metformin as an interven-
tion prior to kidney transplantation, but future research is 
required to investigate whether metformin in combination 
with other potential treatments might be beneficial.
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Kidney transplantation is the treatment of choice for pa-
tients with end-stage renal disease.1 Unfortunately, demand 
is higher than the availability of organs.2 This shortage 
has resulted in increased use of suboptimal quality or-
gans from donation after circulatory death (DCD) donors.3 
Kidneys from DCD donors are more susceptible to isch-
emia-reperfusion injury (IRI), which is linked to significantly 
higher incidences of delayed graft function, affecting both 
short-term and long-term outcome.4,5 IRI is caused by 
the impairment of blood flow and subsequent reoxygen-
ation, which results in the generation of reactive oxygen 
species (ROS), initiating a cascade of detrimental cellular 
responses.6,7 The severity of ischemia correlates strongly 
with early renal graft failure after kidney transplantation and 
contributes to increased morbidity.8 Therefore, warm isch-
emia (WI) during organ retrieval and implantation, and cold 
ischemic time during preservation, respectively, should be 
kept to a minimum. Machine perfusion strategies can play 
a pivotal role in decreasing IRI by supplying oxygen during 
ischemic phases in organ donation. Furthermore, it pro-
vides a platform to add possible protective agents prior to 
reperfusion (preconditioning) or during reperfusion (post-
conditioning), and is a suitable method to assess short-term 
renal function and injury.9–11
The biguanide metformin is the most used oral antihy-
perglycemic drug to treat patients with type 2 diabetes. 
The mechanism of action and the pleiotropic effects of 
metformin primarily results from the inhibition of complex 
1 within the mitochondrial respiratory chain.12–14 Therefore, 
metformin may attenuate IRI beyond its glucose-lowering 
actions, and has been proposed as an organ-protective 
agent during circumstances in which IRI occurs, such as 
transplantation.15,16
The aim of this study was to evaluate potential beneficial ef-
fects of preconditioning and postconditioning with metformin 
on IRI in two different isolated ex vivo normothermic machine 
perfusion (NMP) models using rat and porcine kidneys.
METHODS
Rat study
Animals. Male Lewis rats weighing 270–300  g were 
used (Harlan Laboratories, Boxmeer, The Netherlands). 
The Institutional Animal Care and Use Committee of the 
University of Groningen approved the study protocol 
(DEC6708C). The animals received care according to the 
Dutch Law on Animal Experiments, following the National 
Institute of Health’s Principles of Laboratory Animal Care.
Experimental design, organ retrieval, and preservation. 
A total of 31 rats were divided into 6 groups (n = 5–6 per 
group; Figure 1). In all groups, 15 minutes of WI and 24 hours 
of cold preservation was used to induce ischemic injury. 
Preconditioning was performed by administering 300 mg/
kg metformin (1,1-dimethylbiguanide hydrochloride; Sigma-
Aldrich, St. Louis, MO) dissolved in saline (0.9% NaCl) or 
saline alone through oral gavage 12 and 2  hours before 
nephrectomy. Saline, 30  mg/L metformin or 300  mg/L 
metformin was added to the perfusate as postconditioning 
agent. The concentration of 300  mg/kg body weight 
was chosen, as this dose resulted in serum metformin 
concentrations that correspond to those found in humans 
during maintenance metformin therapy.17
The procurement of kidneys was performed with minor 
changes to the DCD procedure, as described previously.18 In 
short, rats were anaesthetized with 2–5% isoflurane and lapa-
rotomy was performed via a midline incision. Anticoagulation, 
using 500 IU heparin (Leo Pharma, Ballerup, Denmark), was 
administered via the dorsal penile vein. After 15 minutes of 
WI, nephrectomy of the left kidney was performed. The renal 
artery and ureter were cannulated. The kidney was flushed 
in situ with 10  mL saline (37°C) and 5  mL 4°C University 
of Wisconsin (UW) Cold Storage Solution (Bridge to Life, 
Columbia, SC). Once removed, kidneys were flushed with 
5 mL UW once again and stored in UW for 24 hours at 4°C.
Normothermic machine perfusion. The rat NMP method 
has been described extensively earlier.18 In brief, NMP was 
performed for 90  minutes using a roller pump (Ismatec 
ISM404, Zürich, Switzerland). The perfusion pressure was 
set at 102 mmHg, controlled at the renal artery. In the control 
group, the perfusion fluid consisted of 100  mL William’s 
Medium E supplemented with 30  mmol/L HEPES, 50  g/L 
albumin, and 7 mmol/L creatinine (all Sigma-Aldrich). In the 
experimental groups, either 30 or 300 mg/L metformin was 
added to the perfusate. The perfusion fluid was oxygenated 
with 95% oxygen and 5% carbon dioxide with a flow of 0.5 L/
min. The temperature of the perfusion fluid was maintained 
at 37°C using a water bath and heat exchanger (Julabo, 
Seelbach, Germany). The flow was recorded every 10 minutes, 
using a calibrated flow sensor (ME1PXN Inline, Transonic 
Systems, Ithaca, NY). After NMP, biopsies of the kidneys were 
submerged immediately in 4% formaldehyde or snap-frozen 
in liquid nitrogen and subsequently stored at −80°C.
Porcine study
Animals. Kidneys from female Dutch Landrace pigs were 
collected from an abattoir. The animals were stunned and 
exsanguinated according to local standard procedures. 
During exsanguination, approximately 1  L of blood was 
collected in a container containing 25,000 IU unfractionated 
heparin (Leo Pharma). Because slaughterhouse waste 
material was used, no animal ethics committee approval 
was required.
Experimental design, organ retrieval, and 
preservation. To induce ischemic injury, 30  minutes of 
WI was used. After this period, the kidney was flushed 
with 180 mL saline at 4°C. Immediately after the flush, a 
cortical biopsy was taken (Invivo, Best, The Netherlands) 
and stored in 4% buffered formaldehyde. To accommodate 
transport from the abattoir to the laboratory and as a 
preservation technique, the renal artery was cannulated 
and the kidneys were attached to a pulsatile pressure-
controlled hypothermic machine perfusion (HMP) setup 
(Kidney Assist Transport; Organ Assist, Groningen, The 
Netherlands). The kidneys were perfused at 4°C using 
500 mL UW Machine Perfusion Solution for 3 hours (Bridge 
to Life, London, UK) with or without the addition of 2 mg 
metformin, with a mean arterial pressure of 25  mmHg. 
Oxygen (100%) was supplied to the oxygenator (Hilite 
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LT 1000; Medos Medizintechnik AG, Stolberg, Germany) 
with a fixed flow rate of 0.1 L/min.
Normothermic machine perfusion. The kidneys were 
reperfused using an ex vivo NMP setup for 4 hours that was 
described previously.11 In our study, increasing doses of 
metformin or saline were added using an infusion pump. In 
short, after HMP, the renal artery was cannulated and flushed. 
The ureter was cannulated for urine collection. Afterward, the 
kidney was weighed, and a biopsy was taken and stored in 
4% buffered formaldehyde for further analysis. Subsequently, 
the kidneys were placed in an ex vivo pressure-controlled 
NMP circuit. NMP was performed with 500  mL leucocyte 
depleted, (BioR 02 plus; Fresenius Kabi, Bad Homburg, 
Germany) autologous, oxygenated (carbogen, flow 0.5 L/min) 
blood for 4 hours at a mean arterial pressure of 80 mmHg. 
Other compounds added to the perfusion fluid are provided 
in Table S1. In the experimental group, metformin dissolved 
in Ringer’s lactate solution (20 mg/mL; Baxter, Utrecht, The 
Netherlands) was infused using an infusion pump controlled 
by custom-made software in which infusion profiles could 
be defined (Alaris; CareFusion, Rolle, Switzerland). Every 
30 minutes during NMP, the infusion speed was increased 
according to a prespecified schedule (Table S2). This 
schedule was based on human pharmacokinetic data 
indicating that metformin clearance is four times higher 
than the creatinine clearance.19 In the control group, kidneys 
were perfused without the addition of metformin. For each 
experiment, the flow was recorded using the clamp-on flow 
probe (ME7PXL; Transonic Systems), which was attached 
to the tubing close to the renal artery. This flow probe has 
been calibrated for the tubing used. Every 15 minutes during 
NMP, urine was collected and replaced with a corresponding 
volume of Ringer’s lactate solution, which was also recorded. 
The temperature of the perfusion fluid was maintained at 
37°C using an integrated heat exchanger, connected to a 
water bath (Julabo). Blood and urine samples were taken after 
15 and 60 minutes and every following hour for biochemical 
analyses. When NMP was finished, biopsies were taken and 
stored in 4% buffered formaldehyde, or snap-frozen and 
stored at −80°C for further analysis.
Both studies
Biochemical analyses. Perfusate and urine samples 
were centrifuged (1,300  g for 10  minutes in the rat 
model and 1,000 g for 12 minutes in the porcine model, 
Figure 1 Schematic representation of the experimental groups. Groups contain 5–7 kidneys. HMP, hypothermic machine perfusion; 
NMP, normothermic machine perfusion; WIT, warm ischemia time.
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respectively, both at 4°C) and the supernatant was stored 
at −80°C. Lactate dehydrogenase (LDH), aspartate 
aminotransferase (ASAT), and creatinine were determined 
in perfusate, and creatinine in urine, respectively, by 
the Laboratory Center of the University Medical Center 
Groningen using standard biochemical analyses. The 
amount of protein excreted in rat urine was measured using 
a Pierce BCA Protein Assay (Thermo Fisher Scientific, 
Waltham, MA), whereas total protein concentration in 
porcine urine was measured using standard biochemical 
analyses at the Laboratory Center.
Real-time quantitative polymerase chain reaction. 
Real-time polymerase chain reaction (PCR) was carried 
out according to standard procedures on the Taqman 
Applied Biosystems 7900HT Real-Time PCR system, as 
described previously.20 Amplification of gene fragments 
involved in the regulation of vascular tone (endothelin 
1 (EDN-1, encoding for ET-1); endothelial nitric oxide 
synthase (eNOS); and Krüppel-like factor 2 (KLF-2)), 
endothelial activation (Von Willebrand factor (vWF); 
vascular cell adhesion molecule 1 (VCAM-1) and IL-6)), 
and heat-shock protein 70 (HSP-70) was done with primer 
sets listed in Table S3. In short, total RNA was extracted 
from kidney sections using TRIzol (Life Technologies, 
Gaithersburg, MD). The cDNA obtained from rats was 
used as an internal reference during PCR to test primer 
efficiency. Gene expression was normalized with the 
mean of β-actin mRNA content. Results were expressed 
as 2-ΔΔCT, where the CT value represents the difference 
between cycle threshold values.
Morphological scoring. Biopsies stored in 4% 
formaldehyde were embedded in paraffin and were cut 
into 4  µm slices. Coupes were subsequently stained 
with periodic acid-Schiff and scored on proximal tubular 
cell necrosis (ranging from mild to severe: 1–5), edema 
(ranging from mild to severe: 1–4), and proximal tubular 
Figure 2 Perfusion and renal function parameters assessed during and after normothermic machine perfusion of rat and porcine 
kidneys. Total creatinine clearance of rat (a) and porcine (b) kidneys. Total urine production (c, d) and total protein excreted in the urine 
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cell vacuolation (ranging from mild to severe: 1–4).21 
Histopathological assessment was done blinded by two 
researchers. An independent clinical pathologist with 
extensive experience in assessing histopathological signs 
of injury after machine perfusion of rat and porcine organs 
validated the scores.
Calculations. Intrarenal vascular resistance (IVR) was 
calculated by dividing the mean arterial pressure by flow 
(expressed in mmHg/mL  min). Creatinine clearance was 
calculated to estimate glomerular filtration rate using 
the following equation: [creatinine in urine] * urine flow/
[creatinine in perfusate].
Statistical analysis. All data are expressed as 
mean ± standard error of the mean. When comparing two 
groups at a single timepoint, differences were assessed 
using an unpaired Student’s t-test. Differences for total urine 
production, morphological scores, and gene expression 
were tested using analysis of variance. All statistical tests 
are two-tailed and P  ≤  0.05 was considered statistically 
significant. SPSS Statistics version 23 (IBM, Armonk, NY) 
was used for all analyses. The area under the curve (AUC) 
was calculated according to the trapezoid rule, and was 
used to approximate the total creatinine clearance, the total 
amount of protein excreted in the urine, and the total levels 
of ASAT and LDH in the perfusate.
RESULTS
Perfusion parameters
The IVR remained constant during NMP in the rat model, 
without significant differences between the treatment 
groups (Figure S1a). No significant differences were found 
in the porcine kidney groups regarding IVR (Figure S1b).
Kidney function parameters
No significant differences in total creatinine clearance were 
observed between all treatment groups in the rat study 
(Figure 2a). In the porcine study, total creatinine clearance 
did not differ between metformin-treated kidneys and con-
trols (Figure 2b), although there was a tendency toward 
lower creatinine clearance in the metformin-treated group 
(P = 0.07).
Metformin-pretreated rats of whom kidneys were per-
fused with 30 mg/L metformin had a significantly lower urine 
production compared with rats pretreated with metformin 
without subsequent perfusion with metformin (P  =  0.02), 
and rats pretreated with oral saline whose kidneys were 
postconditioned with 30  mg/L metformin (P  =  0.04). 
Postconditioning with 300 mg/L metformin did not yield any 
significant difference in urine production, irrespective of pre-
conditioning conditions. Compared with controls, total urine 
production in porcine kidneys was significantly lower in met-
formin-treated kidneys (P = 0.004; Figure 2c,d).
In the rat study, total protein excretion was lower in 
metformin-preconditioned kidneys without subsequent per-
fusion with metformin than the control group (P = 0.001). No 
differences in total protein excretion were observed between 
all other experimental groups (Figure 2e).
During NMP of porcine kidneys, no significant differences 
in urinary protein excretion were found between the met-
formin and control group (Figure 2f).
Injury markers
Metformin-preconditioned rats whose kidneys were not 
perfused with metformin had lower LDH release than con-
trols (P  =  0.005). Metformin-preconditioned rats whose 
kidneys subsequently were perfused with 30  mg/L met-
formin had lower LDH release than controls (P = 0.01) and 
had a lower LDH release than saline-preconditioned rats 
whose kidneys were perfused with 30  mg/L metformin 
(P = 0.04). Perfusion with 300 mg/L metformin did not result 
in decreased LDH release (Figure 3a). Total LDH release 
during NMP did not differ between metformin-treated por-
cine kidneys and controls (Figure 3b).
Both preconditioning and postconditioning with metformin 
was not associated with a significant difference in the total 
amount of released ASAT in the rat study (Figure 3c). Likewise, 
no differences between metformin-treated kidneys and con-
trols in ASAT levels were found in porcine kidneys (Figure 3d).
Morphological signs of ischemia reperfusion injury
Compared with controls, tubular necrosis was significantly 
reduced in kidneys that were perfused with 300 mg/L met-
formin, independent of saline (P = 0.02) or metformin (P = 0.02) 
preconditioning. Metformin-preconditioned rats whose 
kidneys were perfused with 300 mg/L metformin had less tu-
bular necrosis compared with metformin-preconditioned rats 
without subsequent metformin perfusion (P = 0.01) and met-
formin-preconditioned rats of whose kidneys were perfused 
with 30 mg/L metformin (P = 0.02; Figure 3e).
Proximal tubular cell vacuolation was significantly re-
duced in saline-preconditioned rats whose kidneys were 
perfused with 300  mg/L metformin compared with sa-
line-preconditioned rats whose kidneys were perfused with 
30 mg/L metformin (P = 0.05). Vacuolation was also signifi-
cantly lower in metformin-preconditioned kidneys perfused 
with 300  mg/L metformin compared with metformin-pre-
conditioned kidneys without metformin perfusion (P = 0.02) 
(Figure 3g). No statistical differences regarding edema for-
mation were seen in the rat study (Figure 3f). No differences 
in morphological signs of IRI were observed at the end of 
NMP in porcine kidneys (Figure 3h).
Gene expression
Relative mRNA expression of genes involved in the regu-
lation of the vascular tone was evaluated in both rat and 
porcine kidneys. Compared with controls, the expres-
sion of EDN-1 was significantly decreased in rat kidneys 
perfused with 300 mg/L metformin, regardless of precon-
ditioning with saline (P = 0.002) or metformin (P = 0.005; 
Figure 4a). Compared with saline-pretreated rats whose 
kidneys were perfused with 30 mg/L metformin, eNOS ex-
pression was significantly decreased in controls (P = 0.04) 
and saline-preconditioned rats whose kidneys were per-
fused with 300 mg/L metformin (P = 0.01; Figure 4b). No 
differences regarding EDN-1 or eNOS expression were 
found in the porcine kidney study (Figure 4h).
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KLF-2 expression was not different between groups in 
both the rat and porcine kidney study (Figure 4c,h).
Moreover, genes involved in endothelial activation were 
evaluated. The vWF expression did not differ between treat-
ment groups in both rat and porcine kidneys (Figure 4d,i). 
Compared with controls, gene expression of VCAM-1 was 
significantly decreased in rat kidneys perfused with 30 mg/L 
metformin irrespective of preconditioning with saline 
(P = 0.002) or metformin (P = 0.03). Saline-pretreated rats 
whose kidneys were perfused with 30 mg/L metformin had 
lower VCAM-1 expression than metformin-preconditioned 
rats whose kidneys were also perfused with 30 mg/L met-
formin (P = 0.04). Saline-preconditioned rats whose kidneys 
were perfused with 300  mg/L metformin had significantly 
higher VCAM-1 expression than saline-preconditioned rats 
whose kidneys were perfused with 30  mg/L metformin 
(P  = 0.002). On the other hand, metformin-preconditioned 
rats whose kidneys were perfused with 300 mg/L metformin 
had significantly higher VCAM-1 expression than controls 
(P = 0.03; Figure 4e).
Compared with metformin-preconditioned rats whose 
kidneys were perfused with 300 mg/L metformin, IL-6 gene 
expression was decreased in metformin-preconditioned rats 
whose kidneys were not perfused with metformin (P = 0.03), 
and metformin-preconditioned rats whose kidneys were 
perfused with 30 mg/L metformin (P = 0.004; Figure 4f).
HSP-70 expression in rat kidneys was not different be-
tween treatment groups (Figure 4g). Expression of vWF, 
VCAM-1, and IL-6 was not significantly different between 
experimental groups within the porcine kidney study 
(Figure 4i). However, HSP-70 was upregulated in met-
formin-treated porcine kidneys (P = 0.03; Figure 4l).
DISCUSSION
The aim of this study was to evaluate potential benefits 
of metformin preconditioning and postconditioning on 
IRI in two distinct ex vivo NMP models using rat and pig 
kidneys. We found that, in terms of renal function, met-
formin preconditioning was associated with significantly 
lower proteinuria, representing a favorable effect on glo-
merular integrity.22 In terms of cellular injury, significantly 
lower LDH values were observed in preconditioned rat 
kidneys, whereas postconditioning was not associated 
with differences in this biomarker. Interestingly, postcon-
ditioning with 300 mg/L metformin resulted in less tubular 
cell necrosis and vacuolation. Furthermore, metformin 
preconditioning and postconditioning resulted in gene 
expression upregulation of genes encoding for endothe-
lial activation and inflammation in rats and a significant 
upregulation of HSP-70 in metformin-perfused porcine 
kidneys. The results from this study are indicative that 
metformin has indeed beneficial effects on renal integ-
rity, albeit these effects are minimal and not conclusive. 
Therefore, we did not find a clear answer on whether and 
in which modality metformin can be used as a renopro-
tective strategy to reduce IRI.
To increase the robustness of our findings and to re-
duce potential interspecies effects, two methodological 
distinct ex vivo experimental NMP models were used 
in our study. Because the models differed in so many 
ways, we do not believe the results can be compared di-
rectly, but should be interpreted as two separate albeit 
complementary studies. However, we found beneficial ef-
fects of metformin in the rat study, whereas no apparent 
Figure 3 Injury markers in perfusion fluid and morphological injury in tissue after normothermic machine perfusion. Total markers of 
injury were calculated as the area under the curve. Total amount of lactate dehydrogenase (LDH) (a, b) and aspartate aminotransferase 
(ASAT) (c, d) in the perfusate. Tissue was scored on proximal tubular cell necrosis (ranging from mild to severe: 1–5), edema (ranging 
from mild to severe: 1–4), and proximal tubular cell vacuolation (ranging from mild to severe: 1–4) in the rat study, respectively (e–g). 
Signs of ischemia reperfusion injury in porcine kidneys were scored (h). Data are presented as mean ± standard error of the mean. 
Groups contain 5–7 kidneys. *P < 0.05, **P < 0.01, compared with all other groups.
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differences were found in the porcine experiments. This 
might be explained by differences in experimental design. 
Metformin was administered to rats as a preconditioning 
agent, whereas metformin was only added to porcine kid-
neys during HMP and NMP as a postconditioning agent. 
Because porcine kidneys were obtained from the abattoir, 
we were not able to perform any preconditioning actions. 
Second, metformin was given at the start of NMP in the rat 
study, whereas porcine kidneys were exposed to increas-
ing doses over time. Third, both studies used organs from 
different sexes. Therefore, potential gender effects could 
have arisen, as previous studies showed differences in ef-
fects of brain death on IRI and microcirculation between 
sexes.23,24 Moreover, even sex-dependent differences in 
the anticancer effects of metformin have been reported.25 
Whether this is also the case with metformin used in trans-
plantation settings is worth elucidating.
Remarkably, the administration of metformin in con-
centrations that are associated with toxicity in humans 
was not associated with cellular injury in both our ex vivo 
Figure 4 Relative mRNA expression of genes involved in the regulation of vascular tone, including vasoconstriction (endothelin 1 
(EDN-1)), vasodilatation (endothelial nitric oxide synthase (eNOS)), and laminar flow shear stress (Krüppel-like factor 2 (KLF-2)) in both 
the rat (respectively, a–c) and porcine study (h). Genes involved in the activation of the endothelium, playing a role in platelet (von 
Willebrand factor (vWF)) and leukocyte adhesion (vascular cell adhesion molecule 1 (VCAM-1)), and inflammatory processes (IL-6) were 
assessed in rat (respectively, d–f) and porcine kidneys (i). Heat-shock protein 70 (HSP-70) expression was evaluated as well in both 
rat and porcine kidneys (respectively, g, i). Data are presented as mean ± standard error of the mean. Groups contain 5–7 kidneys. 
*P < 0.05, **P < 0.01.
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models. This is an important finding because metformin can 
accumulate in patients with renal insufficiency and who sub-
sequently can develop severe lactic acidosis.19,26 Our study 
shows that administration of metformin in high doses does 
not induce cellular injury and, therefore, could be safely used 
in ex vivo machine perfusion setups.
Previously, it is reported that preconditioning with met-
formin can reduce IRI.27–29 Protective effects of metformin 
were observed during cerebral ischemia and subsequent 
reperfusion in rats.29,30 In murine myocardial infarction 
models, administration of metformin before ischemia or 
during reperfusion was associated with decreased in-
farction size.28,31 However, these results could not be 
reproduced in a swine model.32 Metformin has also been 
clinically studied as a preconditioning agent to reduce IRI. 
However, neither beneficial effects on myocardial injury 
nor other IRI-reducing effects of metformin precondition-
ing were found in these randomized clinical trials.33,34 
Postconditioning with metformin has also been assessed 
clinically, in which no effects of metformin treatment ini-
tiated after myocardial infarction were observed on renal 
function35 or left ventricular function.36 In previous experi-
ments performed by our group, metformin preconditioning 
of donor rat livers was able to improve hepatobiliary func-
tion during NMP and orthotopic liver transplantation 
thereafter.37
The exact mechanism of action of metformin is unknown, 
but mild inhibition of complex 1 within the mitochondrial 
electron transport chain seems to play a pivotal role.12–14  
Moreover, metformin is thought to affect endothelial 
function through several distinct pathways, including reg-
ulation of nitric oxide production, inhibition of apoptosis, 
and alteration of the cellular energy state with subsequent 
activation of kinase pathways.38–40 In line with previous ex-
periments,39,41 postconditioning with 300 mg/L metformin 
decreases expression of ET-1. Endothelin 1 has proinflam-
matory effects, stimulates ROS production, and modifies 
the glomerular barrier.42 Moreover, elevated ET-1 is as-
sociated with vascular and kidney injury.42,43 Increased 
expression of eNOS was found in rat kidneys perfused 
with a low dose of metformin, which is associated with 
decreased IRI and oxidative stress.38,44,45 However, no dif-
ferences in KLF-2, a marker of fluid laminar shear stress, 
or in vascular resistance itself, were observed. Expression 
of VCAM-1 correlates with severe structural damage of 
renal parenchyma,46 and has previously been reported 
to be less abundant in the metformin-treated kidneys.47 
Moreover, expression of VCAM-1, also involved in leuko-
cyte adhesion, can be induced by ROS in endothelial cells 
during inflammation.48 Indeed, we found reduced VCAM-1 
expression in kidneys perfused with 30 mg/L metformin. 
Summarizing, the findings in gene expression suggest that 
endothelial activation was moderately affected by expo-
sure to metformin.
In our study, we mainly observed a protective effect of 
preconditioning with metformin, implying that metformin 
needs to be administered before the ischemic insult. 
Therefore, a donor intervention should be considered in a 
transplantation setting. Diminishing organ injury by changing 
donor management has been proposed and is performed 
sparsely by others.49,50 However, the logistical and ethical 
issues concerning donor-intervention research hamper per-
forming randomized controlled trials.49 Furthermore, the 
proposed intervention should not negatively affect other or-
gans that are supposed to be transplanted. Therefore, for 
now, the only likely translational use would be ex vivo post-
conditioning with metformin. Machine perfusion modalities 
are increasingly used and are offering an ideal platform for 
pharmacological interventions, like metformin. As postcon-
ditioning with metformin showed some modest beneficial 
effects in our study, it might be tested as a renoprotective 
agent in future research. However, our results do not neces-
sarily advocate the use of metformin as a pharmacological 
intervention prior to kidney transplantation, and we suggest 
it can be considered to be tested in combination with other 
potential treatments.
A limitation reducing the clinical translational aspect of 
our study is the lack of a full kidney transplantation after 
NMP, which should be the direction for further research in 
this field and our study may, therefore, be considered as a 
step toward a transplantation experiment.
Another limitation of our study was that we did not 
measure urinary markers of acute injury, like kidney injury 
molecule 1. However, we did measure indicators of renal 
injury, like LDH and ASAT, that only showed minor benefi-
cial effects of metformin treatment. Future research should 
comprehend these markers when examining effects of met-
formin on renal IRI.
In conclusion, although modest, metformin precondition-
ing prior to NMP was associated with reduced IRI possibly by 
protecting renal integrity, whereas postconditioning with met-
formin was associated with reduced tubular cell necrosis and 
vacuolation, as well as improved endothelial gene expres-
sion. Importantly, no safety signals or potentially irreversible 
damage was observed when exposed to in vivo toxic met-
formin concentrations, indicating that it seems to be safe to 
use these concentrations of metformin during machine perfu-
sion. Our study indicates that both metformin preconditioning 
and postconditioning improved rat and porcine kidney qual-
ity. However, these effects were minor and it remains unclear 
whether metformin can be used as renoprotective strategy 
during machine perfusion before renal transplantation.
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